Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of ravulizumab in pediatric primary IgA nephropathy
CTR20253247Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ravulizumab in IgA nephropathy (IgAN), IgA vasculitis nephritis, sponsored by Alexion Pharmaceuticals. Started Feb 2026; status: active.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)IgA vasculitis nephritis
Beyond the preview
Go deeper on CTR20253247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253247.